|
|
 |
Dr. Dan J. Gelvan, Chairman and CEO
Dr. Gelvan is Managing Director-Life Sciences, Aurum Ventures MKI Ltd. Dr. Gelvan is a seasoned life-science executive who before joining Aurum Ventures managed GammaCan International, Inc. (OTCBB: GCAN), a development-stage pharmaceutical company. Prior to that, Dr. Gelvan founded and managed Zetiq Technologies, a drug discovery company specializing in cell-based high-throughput screening for novel anti-cancer drugs. Dr. Gelvan founded Zetiq after leaving a senior position in Clal (Israel) Ltd., one of Israel's largest holding conglomerates. Dr. Gelvan holds a Ph.D. in Business Economics from RUC in Denmark and he is an experienced lecturer of corporate finance and entrepreneurship. Dr. Gelvan is a member of Israel's National Committee for Biotechnology.
Prof. Yehuda Chowers, MD, Founder, Medical Director and Director
Prof. Chowers is a top-ranking gastroenterology specialist, with a proven track record in the field of medical research. His medical research experience includes a post doctorate (Mucosal Immunology) at the University of California, San Diego and more than 15 years of research experience in the fields of Molecular Biology, Infectious and Inflammatory diseases of the GI tract.
Prof. Joseph R. Pisegna, MD, US Clinical Development
Prof. Pisegna, an expert leader in Clinical Gastroenterology, recently joined Vecta to lead Clinical R&D in the US. Prof. Pisegna is an Associate Professor, Division of Digestive Diseases, Department of Medicine, David Geffen School of Medicine at UCLA. As an expert in the management of gastric acid secretory disorders Prof. Pisegna brings to the company experiences and expertise in both the design of scientific protocols, as well as sharing in our understanding of the marketplace in gastroenterology.
Mr. Tal Atarot, B.Sc.Pharm, M.Sc., VP Regulatory & Clinical Affairs and COO
Mr. Atarot leads the Regulatory and Clinical Affairs activities at Vecta. Prior to joining VECTA, he served as a regulatory affairs specialist and project leader at TEVA Pharmaceuticals Ltd. In addition, Mr. Atarot was a member of R&D teams at the Hebrew University at Jerusalem in the field of pharmaceutical formulation development. Mr. Atarot is a graduate of the Hebrew University at Jerusalem (B.Sc.Pharm summa cum laude) and the Weizmann Institute of Science (MSc in Bioinformatics).
|
